BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 22836717)

  • 1. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study.
    Ardawi MS; Rouzi AA; Al-Sibiani SA; Al-Senani NS; Qari MH; Mousa SA
    J Bone Miner Res; 2012 Dec; 27(12):2592-602. PubMed ID: 22836717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I collagen racemization and isomerization and the risk of fracture in postmenopausal women: the OFELY prospective study.
    Garnero P; Cloos P; Sornay-Rendu E; Qvist P; Delmas PD
    J Bone Miner Res; 2002 May; 17(5):826-33. PubMed ID: 12009013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum sclerostin levels associated with lumbar spine bone mineral density and bone turnover markers in patients with postmenopausal osteoporosis.
    Xu XJ; Shen L; Yang YP; Lu FR; Zhu R; Shuai B; Li CG; Wu MX
    Chin Med J (Engl); 2013 Jul; 126(13):2480-4. PubMed ID: 23823821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study.
    Garnero P; Hausherr E; Chapuy MC; Marcelli C; Grandjean H; Muller C; Cormier C; Bréart G; Meunier PJ; Delmas PD
    J Bone Miner Res; 1996 Oct; 11(10):1531-8. PubMed ID: 8889854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk].
    Mohamed Y; Haifa H; Datel O; Fadoua HN; Smeh BH; Mahbouba J; Saoussen Z; Bejia I; Mongi T; Mohamed FN; Naceur B
    Tunis Med; 2014 May; 92(5):304-10. PubMed ID: 25504382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of serum sclerostin with bone mineral density, bone turnover, steroid and parathyroid hormones, and fracture risk in postmenopausal women: the OFELY study.
    Garnero P; Sornay-Rendu E; Munoz F; Borel O; Chapurlat RD
    Osteoporos Int; 2013 Feb; 24(2):489-94. PubMed ID: 22525978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study.
    Garnero P; Sornay-Rendu E; Claustrat B; Delmas PD
    J Bone Miner Res; 2000 Aug; 15(8):1526-36. PubMed ID: 10934651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab.
    Gatti D; Viapiana O; Fracassi E; Idolazzi L; Dartizio C; Povino MR; Adami S; Rossini M
    J Bone Miner Res; 2012 Nov; 27(11):2259-63. PubMed ID: 22692843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.
    Voskaridou E; Christoulas D; Plata E; Bratengeier C; Anastasilakis AD; Komninaka V; Kaliontzi D; Gkotzamanidou M; Polyzos SA; Dimopoulou M; Terpos E
    Horm Metab Res; 2012 Nov; 44(12):909-13. PubMed ID: 22581647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Independent predictors of all osteoporosis-related fractures among healthy Saudi postmenopausal women: the CEOR Study.
    Rouzi AA; Al-Sibiani SA; Al-Senani NS; Radaddi RM; Ardawi MS
    Bone; 2012 Mar; 50(3):713-22. PubMed ID: 22178778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methylation of bone SOST, its mRNA, and serum sclerostin levels correlate strongly with fracture risk in postmenopausal women.
    Reppe S; Noer A; Grimholt RM; Halldórsson BV; Medina-Gomez C; Gautvik VT; Olstad OK; Berg JP; Datta H; Estrada K; Hofman A; Uitterlinden AG; Rivadeneira F; Lyle R; Collas P; Gautvik KM
    J Bone Miner Res; 2015 Feb; 30(2):249-56. PubMed ID: 25155887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between serum hsCRP concentration and biochemical bone turnover markers in healthy pre- and postmenopausal women.
    Kim BJ; Yu YM; Kim EN; Chung YE; Koh JM; Kim GS
    Clin Endocrinol (Oxf); 2007 Jul; 67(1):152-8. PubMed ID: 17466002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A; Morabito N; Basile G; Brancatelli S; Cucinotta D; Lasco A
    J Clin Endocrinol Metab; 2013 May; 98(5):1911-5. PubMed ID: 23596142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin.
    Gatti D; Viapiana O; Adami S; Idolazzi L; Fracassi E; Rossini M
    Bone; 2012 Mar; 50(3):739-42. PubMed ID: 22178539
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia.
    Kaji H; Imanishi Y; Sugimoto T; Seino S
    Exp Clin Endocrinol Diabetes; 2011 Jul; 119(7):440-4. PubMed ID: 21667439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
    Eastell R; Barton I; Hannon RA; Chines A; Garnero P; Delmas PD
    J Bone Miner Res; 2003 Jun; 18(6):1051-6. PubMed ID: 12817758
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Homocysteine levels and the risk of osteoporotic fracture.
    van Meurs JB; Dhonukshe-Rutten RA; Pluijm SM; van der Klift M; de Jonge R; Lindemans J; de Groot LC; Hofman A; Witteman JC; van Leeuwen JP; Breteler MM; Lips P; Pols HA; Uitterlinden AG
    N Engl J Med; 2004 May; 350(20):2033-41. PubMed ID: 15141041
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
    Zhao J; Xia W; Nie M; Zheng X; Wang Q; Wang X; Wang W; Ning Z; Huang W; Jiang Y; Li M; Wang O; Xing X; Sun Y; Luo L; He S; Yu W; Lin Q; Pei Y; Zhang F; Han Y; Tong Y; Che Y; Shen R; Hu Y; Zhou X; Xu L
    Menopause; 2011 Nov; 18(11):1237-43. PubMed ID: 21747303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of a fully automated serum assay for C-terminal cross-linking telopeptide of type I collagen in osteoporosis.
    Garnero P; Borel O; Delmas PD
    Clin Chem; 2001 Apr; 47(4):694-702. PubMed ID: 11274020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.